Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
:PODD
Holding PODD?
Track your performance easily
PODD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$160.19 - $279.77
Previous CloseN/A
Volume86.50K
Average Volume (3M)544.29K
Market Cap
$19.14B
Enterprise Value$17.71B
Total Cash (Recent Filing)$298.57M
Total Debt (Recent Filing)$332.77M
Price to Earnings (P/E)46.9
Beta1.26
Next Earnings
Feb 20, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.88
Shares Outstanding70,144,775
10 Day Avg. Volume526,475
30 Day Avg. Volume544,294
Standard Deviation0.11
R-Squared0.31
Alpha-0.00046
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.75
Price to Cash Flow (P/CF)49.10
P/FCF Ratio69.70
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue8.93
Enterprise Value/Gross Profit15.27
Enterprise Value/Ebitda67.00
Forecast
1Y Price Target
$299.15Price Target Upside8.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Insulet News
Bulls Say, Bears Say
Bulls Say
Legal VictoryThe U.S. district court delivered a jury trial verdict in favor of PODD against EOFlow, awarding $452M in total damages to PODD.
Regulatory ApprovalPODD received FDA clearance of O5 for patients with type 2 diabetes in late August, roughly three months ahead of the mid-November approval date that was expected.
Technological IntegrationOmnipod 5 being compatible with Abbott’s leading CGM, FreeStyle Libre 2 Plus, is an incremental positive for Insulet.
Bears Say
Competitive PressureCompetitor T2 pump approvals are expected to follow, which could lead to competitive pressure in the T2 segment.
Financial UncertaintyEOFlow's ability to satisfy the damage award is not known with certainty.
Revenue ExpectationsThe updated guidance was seen as a soft spot as it suggests US Omnipod revenue growth below Q4 consensus expectations.
---
Ownership Overview
0.35% Insiders
42.22% Mutual Funds
0.54% Other Institutional Investors
31.33% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $160.19 and its highest was $279.77 in the past 12 months.
What is Insulet’s market cap?
Insulet’s market cap is $19.14B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Feb 20, 2025 which is in 30 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Nov 07, 2024. The company reported $0.9 earnings per share for the quarter, beating the consensus estimate of $0.778 by $0.122.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 1.
How many shares outstanding does Insulet have?
Insulet has 70,144,775 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $0.9 in its last earnings report, beating expectations of $0.778. Following the earnings report the stock price went up 9.397%.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in PODD
---
Insulet Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$299.15 (8.46% Upside)
$299.15 (8.46% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 325.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $139.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.28%
12-Months-Change
Fundamentals
Return on Equity
48.79%
Trailing 12-Months
Asset Growth
22.60%
Trailing 12-Months
Company Description
Insulet
Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
---
PODD Company Deck
---
PODD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Insulet with significant achievements in revenue growth and market expansion, particularly with the Omnipod 5's entry into the type 2 diabetes market. Despite some challenges in U.S. revenue growth and anticipated retention issues in certain type 2 segments, the company's strategic advancements and international success position it well for continued growth.Read More>---
PODD Revenue Breakdown
75.84% U.S.
24.16% International
---
PODD Stock 12 Month Forecast
Average Price Target
$299.15
▲(8.46% Upside)
Technical Analysis
Tandem Diabetes Care
―
Dexcom
―
Atricure
―
Abbott Laboratories
―
Inspire Medical Systems
―
LivaNova
―
Best Analysts Covering PODD
1 Year
1 Year Success Rate
15/18 ratings generated profit
1 Year Average Return
+28.58%
assigned a buy rating last month
Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +28.58% per trade.
---